• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    4/11/24 1:33:07 PM ET
    $ACOR
    $AIH
    $AKAN
    $ALPN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ACOR alert in real time by email

    Shares of Fastenal Company (NASDAQ:FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

    Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents.

    Fastenal shares dipped 6.7% to $69.73 on Thursday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Rallybio Corporation (NASDAQ:RLYB) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.
    • Rent the Runway, Inc. (NASDAQ:RENT) shares jumped 74.5% to $12.91 after the company reported mixed fourth-quarter financial results and issued guidance.
    • Eliem Therapeutics, Inc. (NASDAQ:ELYM) jumped 59.6% to $4.2650. The company announced that it entered into a definitive acquisition agreement to acquire Tenet and it also entered into a securities purchase agreement for a $120 million private placement.
    • Akanda Corp. (NASDAQ:AKAN) gained 36% to $0.1632. Akanda, last month, announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry.
    • Alpine Immune Sciences, Inc. (NASDAQ:ALPN) rose 36.6% to $64.25 after Vertex entered into an agreement to acquire the company.
    • Candel Therapeutics, Inc. (NASDAQ:CADL) surged 29.6% to $6.61 after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer.
    • Enliven Therapeutics, Inc. (NASDAQ:ELVN) gained 26% to $24.97. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.
    • Selina Hospitality PLC (NASDAQ:SLNA) rose 21.1% to $0.0923.
    • Globavend Holdings Limited (NASDAQ:GVH) climbed 16.8% to $1.68.
    • Janux Therapeutics, Inc. (NASDAQ:JANX) gained 16.8% to $52.15 following Wednesday reports suggesting the company is said to weigh a possible sale.
    • SciSparc Ltd. (NASDAQ:SPRC) shares rose 15.3% to $1.9357.
    • Gyre Therapeutics, Inc. (NASDAQ:GYRE) gained 14.6% to $15.91.
    • AnaptysBio, Inc. (NASDAQ:ANAB) climbed 11.4% to $24.72. Wells Fargo analyst Derek Archila initiated coverage on AnaptysBio with an Overweight rating and announced a price target of $56.
    • Verb Technology Company, Inc. (NASDAQ:VERB) gained 10.4% to $0.2010 after gaining 4% on Wednesday.
    • GigaCloud Technology Inc. (NASDAQ:GCT) rose 10.2% to $34.18.
    • Nurix Therapeutics, Inc. (NASDAQ:NRIX) gained 9.6% to $17.21. Baird analyst Joel Beatty maintained Nurix Therapeutics with an Outperform and raised the price target from $24 to $25.
    • StepStone Group LP (NASDAQ:STEP) rose 7.1% to $37.46 after JP Morgan upgraded the stock from Neutral to Overweight.

    Losers

    • Aptevo Therapeutics Inc. (NASDAQ:APVO) shares fell 58% to $1.01 after the company priced its $4.6 million public offering.
    • Enlivex Therapeutics Ltd. (NASDAQ:ENLV) fell 54.5% to $1.81. The company announced topline results of its Phase II trial evaluating Allocetra in sepsis.
    • AVITA Medical, Inc. (NASDAQ:RCEL) fell 28.6% to $10.31 after the company announced an update to its expected commercial revenue for the first quarter of 2024. BTIG downgraded the stock from Buy to Neutral.
    • Aesthetic Medical International Holdings Group Limited (NASDAQ:AIH) fell 19% to $0.3723.
    • Globe Life Inc. (NYSE:GL) fell 14.6% to $89.65.
    • The Lovesac Company (NASDAQ:LOVE) shares fell 14.3% to $20.00 after the company reported worse-than-expected fourth-quarter results and issued first-quarter guidance.
    • Globe Life Inc. (NYSE:GL) fell 13.7% to $90.56.
    • Meiwu Technology Company Limited (NASDAQ:WNW) shares declined 12.4% to $1.1601 after jumping around 32% on Wednesday.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 12% to $0.7660 after declining 14% on Wednesday. Acorda Therapeutics recently commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.
    • CarMax, Inc. (NYSE:KMX) fell 11.7% to $70.02 after the company reported lower-than-expected fourth-quarter earnings.
    • VBI Vaccines Inc. (NASDAQ:VBIV) dipped 11.3% to $0.5641.
    • Nikola Corporation (NASDAQ:NKLA) fell 11.3% to $0.8680. On April 9, Wolfe Research analyst Scott Group initiated coverage on Nikola with a Peer Perform rating.
    • Marin Software Incorporated (NASDAQ:MRIN) declined 10.8% to $0.5798.
    • SolarBank Corporation (NASDAQ:SUUN) fell 9.3% to $5.29. SolarBank closed purchase of 3.15 MW solar project in New York from Storke Renewable.
    • Esperion Therapeutics, Inc. (NASDAQ:ESPR) fell 9.1% to $2.29.
    • 9F Inc. (NASDAQ:JFU) fell 8.8% to $2.7046.
    • iCoreConnect Inc. (NASDAQ:ICCT) shares fell 8.5% to $1.55 after jumping over 50% on Wednesday.
    • ClearOne, Inc. (NASDAQ:CLRO) declined 8.3% to $1.00. The company recently reported fourth-quarter financial results.
    • Nyxoah S.A. (NASDAQ:NYXH) fell 7.3% to $9.83
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 6.2% to $0.8164.
    • Walker & Dunlop, Inc. (NYSE:WD) fell 5.3% to $87.71 after Wedbush downgraded the stock from Outperform to Neutral and lowered its price target from $130 to $95.

     

    Now Read This: Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $AIH
    $AKAN
    $ALPN

    CompanyDatePrice TargetRatingAnalyst
    Avita Medical Inc.
    $RCEL
    3/5/2026$10.00Outperform
    Northland Capital
    StepStone Group Inc.
    $STEP
    3/2/2026$55.00Equal Weight → Overweight
    Barclays
    Nurix Therapeutics Inc.
    $NRIX
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    AnaptysBio Inc.
    $ANAB
    1/7/2026$70.00Buy
    UBS
    Globe Life Inc.
    $GL
    1/6/2026$155.00Outperform → In-line
    Evercore ISI
    Walker & Dunlop Inc
    $WD
    12/19/2025$75.00Buy
    Jefferies
    Fastenal Company
    $FAST
    12/15/2025$52.00Hold → Buy
    Jefferies
    Esperion Therapeutics Inc.
    $ESPR
    11/25/2025$9.00Overweight
    Piper Sandler
    More analyst ratings

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wu Lei

    4 - GigaCloud Technology Inc (0001857816) (Issuer)

    3/20/26 8:52:52 PM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 4 filed by Fox Mary

    4 - Lovesac Co (0001701758) (Issuer)

    3/20/26 7:40:33 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 4 filed by Nelson Shawn David

    4 - Lovesac Co (0001701758) (Issuer)

    3/20/26 7:39:21 PM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Freedman Ernest Michael bought $246,044 worth of shares (5,000 units at $49.21), increasing direct ownership by 456% to 6,097 units (SEC Form 4)

    4 - Walker & Dunlop, Inc. (0001497770) (Issuer)

    3/6/26 4:30:20 PM ET
    $WD
    Finance: Consumer Services
    Finance

    Large owner First Finance Ltd. bought $1,750,000 worth of shares (437,500 units at $4.00), increasing direct ownership by 36% to 1,641,162 units (SEC Form 4)

    4 - CLEARONE INC (0000840715) (Issuer)

    3/6/26 6:02:39 AM ET
    $CLRO
    Telecommunications Equipment
    Utilities

    Director Wells Donna bought $23,480 worth of shares (500 units at $46.96), increasing direct ownership by 10% to 5,277 units (SEC Form 4)

    4 - Walker & Dunlop, Inc. (0001497770) (Issuer)

    3/4/26 4:15:26 PM ET
    $WD
    Finance: Consumer Services
    Finance

    $ACOR
    $AIH
    $AKAN
    $ALPN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $ACOR
    $AIH
    $AKAN
    $ALPN
    SEC Filings

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form F-1/A filed by Akanda Corp.

    F-1/A - AKANDA CORP. (0001888014) (Filer)

    3/20/26 5:17:52 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B3 filed by Enlivex Ltd.

    424B3 - Enlivex Ltd. (0001596812) (Filer)

    3/20/26 4:05:23 PM ET
    $ENLV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Nyxoah SA

    6-K - Nyxoah SA (0001857190) (Filer)

    3/19/26 5:04:44 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Northland Capital initiated coverage on Avita Medical with a new price target

    Northland Capital initiated coverage of Avita Medical with a rating of Outperform and set a new price target of $10.00

    3/5/26 8:30:26 AM ET
    $RCEL
    Medical/Dental Instruments
    Health Care

    StepStone Group upgraded by Barclays with a new price target

    Barclays upgraded StepStone Group from Equal Weight to Overweight and set a new price target of $55.00

    3/2/26 8:29:47 AM ET
    $STEP
    Investment Managers
    Finance

    Nurix Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Nurix Therapeutics from Equal-Weight to Overweight and set a new price target of $36.00

    1/8/26 8:12:12 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Publication relating to transparency notifications

    REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), March 20, 2026, 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Robert Taub / Robelga SRL On March 19, 2026, Nyxoah received a transparency notification from Robert Taub and related person Robelga SRL, following the crossing above the 3% threshold by Robelga SRL on December 30, 2025 (while the overall "group" participation did not change). Based on the notification, Robert Taub (together with his

    3/20/26 5:30:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    GigaCloud Technology Inc Announces Marketplace Initiative with Otto Group to Expand Assortment in Europe

    EL MONTE, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (NASDAQ:GCT) ("GigaCloud" or the "Company"), a pioneer of global end-to-end B2B ecommerce technology solutions for large parcel merchandise, today announced a marketplace initiative with Otto Group, one of Europe's largest ecommerce and retail enterprises. As part of this initiative, GigaCloud will facilitate the introduction of select sellers, including leading furniture brands and suppliers, to Otto's established European selling platform. The initiative is intended to broaden marketplace assortment while leveraging GigaCloud's global supplier network and technology capabilities. "This collaboration aligns wi

    3/20/26 7:00:00 AM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary

    CarMax Announces Fourth Quarter Conference Call

    CarMax, Inc. (NYSE:KMX) will report its financial results for the fourth quarter ended February 28, 2026 before the market opens on April 14, 2026, and it will host a conference call with investors at 9:00 a.m. ET to discuss these results. Participants on the call will include Tom Folliard, Interim Executive Chair of the Board, Keith Barr, President and CEO, Enrique Mayor-Mora, Executive Vice President, CFO and Jon Daniels, Executive Vice President, CarMax Auto Finance. The live conference call can be accessed by dialing (800) 225-9448 (or (203) 518-9708 for international access) and entering the conference ID 3171396. A live audio webcast also will be available at investors.carmax.com.

    3/19/26 5:00:00 PM ET
    $KMX
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Leadership Updates

    Live Leadership Updates

    View All

    Starboard Delivers Letter to CarMax

    Views Appointment of New CEO Keith Barr as Timely Opportunity to Address Fixable Execution Gaps and Unlock CarMax's Full Value Potential Has Nominated Directors to Help Support the Next Phase of Execution and Accelerate Shareholder Value Creation Believes CarMax's Structurally Superior Omnichannel Model Is Not Reflected in Current Performance Sees Clear Opportunities to Drive Improvement Through Enhanced Digital Execution, Reconditioning Efficiencies and Dynamic Pricing Urges a Substantially Expanded SG&A Reduction Program to Restore Cost Discipline and Enhance Long-Term Earnings Power Starboard Value LP (together with its affiliates, "Starboard"), a significant stockholder of Car

    3/11/26 8:00:00 AM ET
    $KMX
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Rent the Runway Appoints Dhiren Fonseca as Executive Chairman

    NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- Rent the Runway, Inc. ("Rent the Runway" or the "Company") (NASDAQ:RENT), the company that is transforming the way women get dressed, today spotlights the appointment of Dhiren Fonseca as Executive Chairman of the Board of Directors, who has served since October 2025. Fonseca is a seasoned business leader with a distinguished track record of scaling high-growth technology and consumer companies. His extensive experience spans private equity, travel, and digital commerce, making him uniquely positioned to guide Rent the Runway as it continues to innovate its platform, deepen its supplier relationships, and explore strategic partnerships. "Dhire

    3/9/26 9:15:00 AM ET
    $RENT
    Other Specialty Stores
    Consumer Discretionary

    Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Reported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026Key data readout, regulatory interactions, and operational catalysts throughout 2026Strong balance sheet with $463 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year e

    3/3/26 4:05:00 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Financials

    Live finance-specific insights

    View All

    CarMax Announces Fourth Quarter Conference Call

    CarMax, Inc. (NYSE:KMX) will report its financial results for the fourth quarter ended February 28, 2026 before the market opens on April 14, 2026, and it will host a conference call with investors at 9:00 a.m. ET to discuss these results. Participants on the call will include Tom Folliard, Interim Executive Chair of the Board, Keith Barr, President and CEO, Enrique Mayor-Mora, Executive Vice President, CFO and Jon Daniels, Executive Vice President, CarMax Auto Finance. The live conference call can be accessed by dialing (800) 225-9448 (or (203) 518-9708 for international access) and entering the conference ID 3171396. A live audio webcast also will be available at investors.carmax.com.

    3/19/26 5:00:00 PM ET
    $KMX
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of SalesFoundation Established to Drive Significant Growth in 2026 Mont-Saint-Guibert, Belgium – March 19, 2026, 9:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year of 2025. Recent Financial and Operating Highlights Fourth quarter gross revenue of €6

    3/19/26 4:10:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    The Lovesac Company Announces Fourth Quarter and Fiscal 2026 Conference Call Date

    STAMFORD, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- The Lovesac Company (NASDAQ:LOVE) ("Lovesac" or the "Company"), the Designed for Life home and technology brand, today announced that its fourth quarter and fiscal 2026 financial results will be released before market open on Thursday, March 26, 2026. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 877-407-3982 (international callers please dial 201-493-6780) approximately 10 minutes prior to the start of the call. A live audio webcast of the conference call will be available online at investor.lovesac.co

    3/12/26 7:00:00 AM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    $ACOR
    $AIH
    $AKAN
    $ALPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by iCoreConnect Inc.

    SC 13G/A - iCoreConnect Inc. (0001906133) (Subject)

    12/12/24 9:44:00 PM ET
    $ICCT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13D/A filed by GigaCloud Technology Inc

    SC 13D/A - GigaCloud Technology Inc (0001857816) (Subject)

    12/12/24 3:02:53 PM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary